Podcasts about hbv

With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials.Moderator: Ahmed Elsharkawy Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su WangThis EASL Studio is supported by Aligos Therapeutics and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics or Gilead Sciences Europe Ltd with regards to the content of this programme.All EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.

From the 2024 International Hepatitis B virus meeting in Chicago IL, Rich Condit speaks with Thomas Tu about his experiences as a both a HepB scientist and patient. Host: Rich Condit Guest: Thomas Tu Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Hepatitis B Foundation Tu Laboratory Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

From the 2024 International Hepatitis B virus meeting in Chicago IL, Rich Condit speaks with Chari Cohen about her work as President of the Hepatitis B Foundation. Host: Rich Condit Guest: Chari Cohen Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Hepatitis B Foundation Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

From the 2024 International Hepatitis B virus meeting in Chicago IL, Rich Condit speaks with Stephan Urban about his career working on HBV and HDV, and his philanthropy. Host: Rich Condit Guest: Stephan Urban Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV ASV 2025 Hepatitis delta: recent advances (Hepatology) Bulevirtide for HBV and HDV (Lancet Inf Dis) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

In this episode, Patricia D. Jones, MD, MSCR; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and patient advocate, Jennifer Wild, MS, RN, OCN, discuss practical strategies to overcome barriers to hepatitis B virus (HBV) care, including: Overcoming health insurance navigation Improving access to HBV care in immigrant communitiesDispelling HBV myths and stigmaSolutions to language barriersCommunity-based interventionsPresenters:Patricia D. Jones, MD, MSCRAssociate Professor of Clinical MedicineDirector of Clinical Operations-HepatologyDivision of Digestive Health and Liver DiseasesDepartment of MedicineUniversity of Miami Miller School of MedicineSylvester Comprehensive Cancer CenterMiami, FloridaMindie H. Nguyen, MD, MAS, AGAF, FAASLDProfessor of Medicine (GI & Hepatology,Liver Transplant)Professor of Epidemiology & Population Health(by Courtesy)Director of Hepatology ClerkshipFaculty Search LENS Advocates,Stanford Department of MedicineFaculty Fellow, Stanford Center for Innovationin Global HealthMember, Stanford Cancer Institute, Maternal &Child Health Research Institute, & Stanford Bio-CStanford, CaliforniaPast Chair: HBV SIG, The American Association for the Study of Liver Diseases (AASLD)28th President: The International Association for the Study of the Liver (IASL)Jennifer Wild, MS, RN, OCNClinical Nurse – GI Medical OncologyUCSF Cancer CenterSan Francsico, CaliforniaLink to full program: https://bit.ly/4j973TNDownloadable slides: https://bit.ly/3WQkIWlGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Deine Chance auf einen Job im Sportbusiness

Send us a textDr. Chari A. Cohen, DrPH, MPH ( https://blumberginstitute.org/faculty/chari-a-cohen/ ) is the President of the Hepatitis B Foundation ( https://www.hepb.org/ ), a global nonprofit dedicated to finding a cure and improving the quality of life for people affected by hepatitis B worldwide.Dr. Cohen conducts research and implements programs to reduce health disparities and improve health outcomes associated with hepatitis B, as well as hepatitis D, and liver cancer. Dr. Cohen is also co-chair of the Hep B United Coalition, co-founder and chair of Hep B United Philadelphia, co-founder and chair of CHIPO: Coalition Against Hepatitis for People of African Origin; and immediate past co-chair of the Hep Free PA Coalition. Dr. Cohen is also a member of the International Coalition to Eliminate of HBV (ICE-HBV) steering committee, HepVu advisory committee (an online platform that visualizes data and disseminates insights on the viral hepatitis epidemic across the U.S), and HBV Forum for Collaborative Research. Dr. Cohen serves as both a Professor at the Baruch S. Blumberg Institute, and adjunct faculty for Geisinger Commonwealth School of Medicine. Dr. Cohen received her DrPH in Community Health and Prevention from Drexel University and her MPH from Temple University.The Baruch S. Blumberg Institute ( https://blumberginstitute.org/ ) is a nonprofit translational research organization focused on understanding the pathobiology of hepatitis B virus and related diseases, developing diagnostics for early detection of liver cancer, and discovering therapeutics, antivirals and immune modulators for the cure of chronic HBV and other RNA viruses that cause hepatitis and hemorrhagic fever.#ChariCohen #HepatitisBFoundation #HepBVaccine #BaruchSBlumberg #LiverCancer #Cirrhosis #AntiVirals #HarmReduction  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

In this episode, Patricia D. Jones, MD, MSCR; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and patient advocate, Jennifer Wild, MS, RN, OCN, discuss best practices in hepatitis B virus (HBV) care, including: 2023 CDC HBV screening recommendationsSummary of guideline recommendations for hepatitis delta virus (HDV) screening Use of HDV reflex testing to avoid loss to follow-up2024 WHO HBV treatment recommendations, including recommendations for pregnant persons Presenters:Patricia D. Jones, MD, MSCRAssociate Professor of Clinical MedicineDirector of Clinical Operations-HepatologyDivision of Digestive Health and Liver DiseasesDepartment of MedicineUniversity of Miami Miller School of MedicineSylvester Comprehensive Cancer CenterMiami, FloridaMindie H. Nguyen, MD, MAS, AGAF, FAASLDProfessor of Medicine (GI & Hepatology,Liver Transplant)Professor of Epidemiology & Population Health(by Courtesy)Director of Hepatology ClerkshipFaculty Search LENS Advocates,Stanford Department of MedicineFaculty Fellow, Stanford Center for Innovationin Global HealthMember, Stanford Cancer Institute, Maternal &Child Health Research Institute, & Stanford Bio-CStanford, CaliforniaPast Chair: HBV SIG, The American Association for the Study of Liver Diseases (AASLD)28th President: The International Association for the Study of the Liver (IASL)Jennifer Wild, MS, RN, OCNClinical Nurse – GI Medical OncologyUCSF Cancer CenterSan Francsico, CaliforniaLink to full program: https://bit.ly/4j973TNDownloadable slides: https://bit.ly/3WQkIWlGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

HIV Matters takes listeners to Sierra Leone in this compelling episode. Michelle welcomes Prof Simon Taylor-Robinson and Álvaro del Valle Palacios to discuss the vital work of MINI's Village Foundation. They'll explore the challenges of HIV/AIDS and hepatitis B in Sierra Leone and how MVF is providing free healthcare and education to combat these diseases and reduce stigma.Episode GuestsProf Simon Taylor-RobinsonSimon is a hepatology professor at Imperial College London and former Dean of its School of Medicine, is a Fellow of the Royal College of Physicians and the West African College of Physicians. With extensive HBV project experience in West Africa, he holds an honorary Professorship at the Nigerian Institute of Medical Research.Álvaro del Valle PalaciosÁlvaro is a lawyer with a LLB from Complutense University of Madrid and a PGCert in Human Rights Law from SOAS, is completing a MA in Corporate Communications. He serves as an executive member and Director for Media and Communications for MVF.Additional Information and Links CW Plushttps://www.cwplus.org.uk/HIV Matters Bookstorehttps://uk.bookshop.org/shop/HIVMattersHow to contact the show Hello@hivmatterspodcast.co.ukhttps://hiv-matters.captivate.fm

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Kenneth Sherman of Massachusetts General Hospital and Harvard Medical School about the possibility of a cure for hepatitis B. The World Health Organization estimates that 254 million people were living with chronic hepatitis B globally in 2022. Dr Saag and Dr Sherman discuss the lifecycle of hepatitis B including the role that covalently closed circular DNA (cccDNA) plays in the hepatitis B virus (HBV) replication cycle. Dr Sherman defines functional cure and provides an overview of the most promising cure strategies. They also discuss whether antiretroviral drugs like tenofovir, used in the treatment of HIV, can contribute toward a functional cure of hepatitis B. Dr Sherman discusses other strategies like capsid assembly modulators (CAMs), monoclonal antibodies, and toll-like receptor (TLR) agonists. Finally, they discuss the effectiveness of the hepatitis B vaccine in prevention and look forward to the future by considering a timeline for a cure based on the status of ongoing clinical trials. 0:00 – Introduction1:23 – Overview of the lifecycle of hepatitis B 5:29 – Discussion of the most promising cure strategies7:11 – Defining functional cure10:56 – The role of drugs like tenofovir in a functional cure 13:39 – Targets that can affect viral production 16:04 – Potential of capsid assembly modulators (CAMs)18:03 – Other strategies like immune modulators and monoclonal antibodies22:29 – Interest in toll-like receptor (TLR) agonists and therapeutic vaccines24:32 – Outlook for the future and the effectiveness of a hepatitis B vaccine in prevention __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

From the 2024 International Hepatitis B virus meeting in Chicago, TWiV speaks with Mala Maini and John Tavis about their careers, the replication and transmission of HBV, and the HBV Foundation. Hosts: Vincent Racaniello and Rich Condit Guests: Mala Maini and John Tavis Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server Immunobiology and pathogenesis of hepatitis B virus infection (Nat Rev Immunol) HBV Foundationhttps://www.hepb.org/ Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Techmiljardären Elon Musk lottar ut en miljon dollar om dagen till Trumpväljare och det kan vara olagligt. Det första HBV-hemmet för HBTQI+-ungdomar öppnar, Marcus och Martinus anmäler norsk tidning för ett nazistskämt och Fittjaskolan gör konst om skjutningar. Lyssna på alla avsnitt i Sveriges Radio Play.

Okužbo z bakterijo Helicobacter pylori moramo čim prej odkriti in zdravitiGastroenterolog prof. dr. Bojan Tepeš (NIJZ, MF Ljubljana, Rogaška Slatina) si prizadeva, da bi v Sloveniji zaživel program zgodnjega odkrivanja in zdravljenja okužbe z bakterijo Helicobacter pylori. Prav njo namreč lahko povežemo s kroničnim gastritisom in z nastankom razjed na želodcu ali dvanajstniku. Bakterijo Helicobacter pylori lahko okrivimo za številne primere raka na želodcu. Zato v Zdravstvenem domu Maribor in v Zdravstvenem domu Ljubljana vabijo vse, ki so stari med 30 in 34 let na testiranje na Helicoacter pylori. V Sloveniji je namreč okuženih kar približno 25 odstotkov ljudi, vendar mnogi za okužbo sploh ne vejo. Foto: CDC/Dr. Patricia Fields, Dr. Collette Fitzgerald (PHIL #5715), 2004/ PublicDomain Testiranje v ZD Maribor (EUROHELICAN) TUKAJ Testiranje v ZD Ljubljana (TOGAS) TUKAJ

Have you ever had a virus that lingers, or even recurs? There are a group of viruses known as ‘persistent viruses'' that can linger in our bodies for years. Examples include; long covid, herpes, hepatitis (HBV or HCV), epstein-barr virus (EBV), chronic fatigue and many more. Host Amelia Phillips and author Lee Holmes discuss how these viruses impact our health and how a low histamine and low inflammatory approach may help.  In Lee's latest book Natures way to healing: A long covid guide, she shares her own long covid experience, plus latest research, and many low inflammatory, low histamine recipes. Purchase her book here: https://www.booktopia.com.au/nature-s-way-to-healing-lee-holmes/book/9781922786043.html  About the guest: Lee Holmes is a qualified clinical nutritionist, whole-foods chef and author of nine bestselling books including: Supercharged Food: Heal Your Gut, which has been reprinted 12 times. She owns a health food brand and appears regularly in the media.  Follow Lee on Instagram: https://www.instagram.com/leesupercharged/  About the host: Amelia Phillips is a registered exercise scientist and nutritionist with a career spanning 26 years in health. She's a registered exercise scientist, nutritionist and researcher (with a Masters of Human Nutrition). She was the co-founder of health tech company 12WBT which grew from start-up and more recently Inner Vitality, an 8 week online program using biomarkers and personalised health that she runs with an Integrative GP.  Amelia also consults to health companies, presents and appears in the media, most recently on the Ch9 show Do You Want to Live Forever. Amelia had four kids in five years and is dedicated to empowering women to build a life after kids on the foundation of health (mental and physical), connection and purpose.  If you have a question for Amelia, reach out via Insta @_amelia_phillips, email ap@ameliaphillips.com.au  Find out more at www.ameliaphillips.com.au Find out more about Inner Vitality, a new approach to your health: https://innervitality.ameliaphillips.com.au/pages/  CREDITSHost: Amelia Phillips                                                                                                        Guest:  Lee Holmes                                                                                                              Audio Producer: Darren RothMusic: Matt Nicholich                                                                                                      Production Partner: Nova Entertainment Pty Ltd Healthy Her acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures. See omnystudio.com/listener for privacy information  See omnystudio.com/listener for privacy information.

In this episode, George Lau, MD, FRCP (Edin, Lond), FHKAM (Med), FHKCP, FAASLD, MBBS (HKU), and a patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including: Consequences to poor adherence to antiviral therapyStrategies to promote medication adherence (eg, patient education, setting up routines)The role of routine monitoring to prevent complications related to HBV such as hepatocellular carcinoma  Presenter: George Lau, MD, FRCP (Edin, Lond), FHKAM (Med), FHKCP, FAASLD, MBBS (HKU)Specialist in Gastroenterology & HepatologyChairman and Senior Consultant in Gastroenterology and HepatologyHumanity and Health Medical GroupHong Kong, ChinaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: https://bit.ly/49TuZ8UGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Responsible for 1.3 million deaths and 2.2 million new infections per year, viral hepatitis is the second leading cause of morbidity and mortality amongst all infectious diseases, just behind tuberculosis.  Hosts Angela Huttner and Oana Sandulescu welcome special guest and leading hepatitis expert, Professor Mojca Matičič, MD, PhD (Ljubljana, Slovenia), to refresh your knowledge on the pathogenesis of hepatitis B & C infections, review the latest direct-acting antiviral (DAA) therapies, map out some countries' successful elimination initiatives, and understand challenges remaining for others. In recognition of World Hepatitis Day this Sunday, 28 July, a day dedicated to raising awareness about viral hepatitis, we are releasing our latest episode a few days early. The World Hepatitis Day theme this year is: it's time for action! The Communicable team urges our listeners to inform themselves and others, and to test, treat, and vaccinate against viral hepatitis.  This episode was peer reviewed by Dr. Liem Luong of CIC Cochin Pasteur, Hôpital Cochin-Port Royal, Assistance Publique-Hôpitaux de Paris, Paris, France. LiteratureWorld Hepatitis Day 2024: It's time for action. Geneva: World Health Organization; 2024. https://www.who.int/campaigns/world-hepatitis-day/2024 Method for global reporting on disease burden and service coverage data for viral hepatitis B and C, 2022. In: Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. doi: 10.2471/B09024. The European Association of the Study of the Liver (EASL). EASL Congress Milan, Italy 5-8 June 2024. https://www.easlcongress.eu/European Centre for Disease Prevention and Control (ECDC). ECDC Evidence brief: Prevention of hepatitis B and C in the EU/EEA. Stockholm: ECDC; 2024.  European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2022. Stockholm: ECDC; 2024.  Burnet Institute and Kirby Institute. Australia's progress towards hepatitis C elimination: annual report 2022. Melbourne: Burnet Institute; 2022. Maticic M, Pirnat Z, Leicht A, et al. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J. 2020 Nov 19;17(1):89. doi: 10.1186/s12954-020-00439-3.

In this episode, Michelle chats with Dr Philip Ambulai and Rebecca Kanu about Mini's Village Foundation.Subject Description - Mini's Village Foundation (MVF)By 2025, MVF aims to raise awareness and provide screening for HIV and HBV, enabling early treatment interventions and combating the stigma associated with these conditions in Sierra Leone. MVF's mission is to support sexual disease awareness, immunisation, and treatment initiatives, particularly for young people aged 14-50 years. Committed to delivering high standards of safety and compassionate care, MVF collaborates with patients, families, medical professionals, and communities. Their core values include respect, integrity, and teamwork, ensuring patient needs are at the heart of their sustainable services.Episode Guest - Dr Philip AmbulaiDr. Philip Lahai Ambulai is the CEO and Director of a leading micro medical diagnostic company and the Founder and Director of Mini's Village Foundation (MVF), a UK-registered not-for-profit organization (registration number 1205457). With over 15 years of clinical and research expertise, Dr. Ambulai is dedicated to advancing healthcare solutions. MVF, under his leadership, provides free healthcare services to individuals living with HIV/AIDS, HBV, and STDs in Sierra Leone, reflecting his commitment to improving health outcomes for vulnerable populations.Episode Guest - Miss Rebecca KanuRebecca Kanu is the Co-Founder of MVF and currently works as a Senior Clinical Research Coordinator. Named in honor of Rebecca's mother, Mini, who contracted HIV through a needle stick injury while serving as a nurse, MVF embodies a deep commitment to healthcare and community support. Rebecca plays a pivotal role in advancing MVF's mission to combat the stigma associated with HIV/AIDS and HBV in Sierra Leone. Mini's Village Foundation LinksWebsite - https://www.minisvillagefoundation.orgEmail - info@minisvillagefoundation.orgContact Number - +44 (0) 7852 148177Additional Information and Links National HIV Nurse Association (NHIVNA) www.nhivna.org.HIV Matters Bookstorehttps://uk.bookshop.org/shop/HIVMattersHow to contact the show Hello@hivmatterspodcast.co.ukhttps://hiv-matters.captivate.fm

TWiV discusses presence of infectious avian H5N1 influenza virus in raw milk from infected dairy cows. dynamics of measles immunity from birth and following vaccination, and a mechanism for cis-preferential reverse transcription revealed by deep mutational scanning of hepatitis B virus. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress 2024 International HBV Meeting Michelson Prizes: Next Generation Grants Register for ASV Annual Meeting H5N1 influenza virus in raw cow milk infects mice (NIAID News) Dynamics of measles virus immunity from birth (Nat Comm) Mechanism of cis-preferential HBV reverse transcription (Cell) Timestamps by Jolene. Thanks! Weekly Picks Dickson – Oldest virus in Neanderthal bones Brianne – Jeopardy! winner reveals entwined memory systems make a trivia champion Kathy – Bright future of intelligent fabrics primary article and Self-dyeing textiles (primary article) Rich – Farewell to HD Atlas; Boston Dynamics Retires HD Atlas Robot Alan – Why vaccinating cattle against H5N1 is hard Vincent – Singapore Airlines turbulence: why climate change is making flights rougher Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Become a pro in Hepatitis B! Dr. Arthur Kim teaches us how to approach Hepatitis B screening and vaccination in primary care, provides pearls on counseling patients with chronic Hepatitis B infection, and summarizes considerations for Hepatitis B antiviral treatment and monitoring. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case from Kashlak Hepatitis B screening - who should be screened? Hepatitis B screening - interpreting test results Hepatitis B vaccination Stages of Chronic HBV infection Counseling patients with chronic HBV about preventing transmission and protecting liver health Treatment of chronic HBV infection Screening for hepatocellular carcinoma Outro Credits Producer, Writer, Show Notes, Infographics, and Cover Art: Malini Gandhi  Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Fatima Syed MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Arthur Kim MD Sponsor: Babbel Get up to 60% off your Babbel subscription Babbel.com/curb Sponsor: Freed You can try Freed for free by going to freed.ai. Use code CURB50 for $50 off your first month.  Sponsor: Pattern Request your disability insurance quotes with Pattern at patternlife.com/curbsiders.

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:Engage key stakeholders in the provision of HBV care​Provide HBV management resources to support PCPs who are doing screening​Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBVPresenters:Su Wang, MD, MPH, FACPMedical DirectorCenter for Asian Health and Viral Hepatitis ProgramsCooperman Barnabas Medical CenterRWJBarnabas-Rutgers Medical GroupAssociate MemberHealth Care Policy and Aging ResearchThe Rutgers Institute for HealthSenior AdvisorGlobal Health, Hepatitis B FoundationFlorham Park, New JerseyRichard R. Andrews, MD, MPHPresident, Houston Viral Hepatitis Task ForceFormer Co-Chair, National Task Force on Hepatitis BBoard-Certified Family MedicineAddiction Medicine PhysicianHouston, TexasRuth Brogden, MPHPatient AdvocateAmy S. Tang, MDFormer Co-Chair, National Task Force on Hepatitis BDirector of Immigrant HealthNorth East Medical ServicesSan Francisco, CaliforniaLink to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/44hXpHuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:Engage key stakeholders in the provision of HBV care​Provide HBV management resources to support PCPs who are doing screening​Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBVPresenters:Su Wang, MD, MPH, FACPMedical DirectorCenter for Asian Health and Viral Hepatitis ProgramsCooperman Barnabas Medical CenterRWJBarnabas-Rutgers Medical GroupAssociate MemberHealth Care Policy and Aging ResearchThe Rutgers Institute for HealthSenior AdvisorGlobal Health, Hepatitis B FoundationFlorham Park, New JerseyRichard R. Andrews, MD, MPHPresident, Houston Viral Hepatitis Task ForceFormer Co-Chair, National Task Force on Hepatitis BBoard-Certified Family MedicineAddiction Medicine PhysicianHouston, TexasRuth Brogden, MPHPatient AdvocateAmy S. Tang, MDFormer Co-Chair, National Task Force on Hepatitis BDirector of Immigrant HealthNorth East Medical ServicesSan Francisco, CaliforniaLink to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/44hXpHuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:Engage key stakeholders in the provision of HBV care​Provide HBV management resources to support PCPs who are doing screening​Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBVPresenters:Su Wang, MD, MPH, FACPMedical DirectorCenter for Asian Health and Viral Hepatitis ProgramsCooperman Barnabas Medical CenterRWJBarnabas-Rutgers Medical GroupAssociate MemberHealth Care Policy and Aging ResearchThe Rutgers Institute for HealthSenior AdvisorGlobal Health, Hepatitis B FoundationFlorham Park, New JerseyRichard R. Andrews, MD, MPHPresident, Houston Viral Hepatitis Task ForceFormer Co-Chair, National Task Force on Hepatitis BBoard-Certified Family MedicineAddiction Medicine PhysicianHouston, TexasRuth Brogden, MPHPatient AdvocateAmy S. Tang, MDFormer Co-Chair, National Task Force on Hepatitis BDirector of Immigrant HealthNorth East Medical ServicesSan Francisco, CaliforniaLink to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/44hXpHuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Karoonka Swedishka ee daciifka ah ayaa keenay in dalxiisayaasha Danishku ay ku soo qulqulaan Iswiidhen. In haweenka uurka lihi liqaan xanuun baabi'iyaha paracetamol ma kordhinayso khatarta ah in ilmuhu qaado xaaladda autism, ADHD ama naafo maskaxeed. Maxkamada degmada Falu ayaa degmada Falu ka fasaxday inay magdhow siiso waalidka wiil shan jir ahaa oo lagu hayey guryaha dhallaanka lagu xanaaneeyo HBV-hem-ka oo geeriyooday.

In this episode, Maria Buti, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including: Barriers to HBV screening, including patient- and provider-specific barriers (eg, lack of education, failure to disclose or discuss risk factors, perceived low risk, stigma)Applying CDC recommendations for universal HBV screening in adults Strategies to improve HBV transitions of care (eg, improved education, simplify criteria for screening and monitoring, alternative testing sites)Importance of testing close contacts for HBV after initial diagnosis and promoting HBV vaccination Presenter: Maria Buti, MDProfessor of MedicineSenior ConsultantLiver UnitHospital Universitario Valle HebronBarcelona, SpainContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/49TuZ8UGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Visit nascentmc.com/podcast for full show notes Winrevair for PAH: Sotatercept-csrk (Winrevair) is FDA-approved for treating adults with pulmonary arterial hypertension (PAH), enhancing exercise capacity, improving WHO functional class, and reducing clinical worsening events. It's the first FDA-approved activin signaling inhibitor for PAH, addressing the imbalance in vascular cell proliferation underlying the condition. The approval is based on the Phase 3 STELLAR trial, demonstrating significant improvements in walk distance and reduced risk of clinical worsening events [1]. Vafseo for CKD: Vadadustat (Vafseo) is approved for managing anemia due to chronic kidney disease (CKD) in adult dialysis patients. As an oral HIF-PH inhibitor, it stimulates endogenous erythropoietin production, offering a novel approach to anemia management. Approval is supported by efficacy and safety data from the INNO2VATE program and post-marketing safety data from Japan [2]. Ultomiris for NMOSD: Ravulizumab-cwvz (Ultomiris) is FDA-approved for treating neuromyelitis optica spectrum disorder (NMOSD) in patients with anti-AQP4 antibodies. It's a terminal complement C5 inhibitor administered once every two months, demonstrating efficacy in preventing relapses. Approval is based on the Phase 3 CHAMPION-NMOSD study, showing significant reductions in relapse risk compared to placebo [3]. Evolut FX+ for TAVR: The Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system is FDA-approved for treating symptomatic severe aortic stenosis. It features enhancements for improved catheter maneuverability without compromising effectiveness. The approval expands treatment options for patients across all risk categories [4]. Vemlidy for Pediatric HBV: Tenofovir alafenamide (Vemlidy) is FDA-approved for treating chronic hepatitis B virus (HBV) infection in pediatric patients aged 6 years and older with compensated liver disease. It's a preferred or first-line treatment option, addressing a significant medical need. Approval is based on the Phase 2 clinical trial 1092, demonstrating efficacy and safety in this patient population [5]. Pemgarda for COVID: Pemgarda, a monoclonal antibody, is FDA-approved for preventive use in immunocompromised individuals aged 12 and older against COVID-19. It prevents virus attachment and has shown promising results in reducing symptomatic COVID-19 cases. Approval is based on emergency use authorization and preliminary data from the CANOPY Phase 3 clinical trial [6].

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Episode 164: More Than Just A HeadacheDr. Song presents a case of a subacute headache that required an extensive workup and multiple visits to the hospital and clinic to get a diagnosis. Dr. Arreaza added comments about common causes of subacute headaches.    Written by Zheng (David) Song, MD. Editing and comments by Hector Arreaza, MD.  You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Introduction to the episode: We are happy to announce the class of 2027 of the Rio Bravo / Clinica Sierra Vista Family Medicine Residency Program. Our new group will be (in alphabetical order): Ahamed El Azzih Mohamad, Basiru Omisore, Kenechukwu Nweke, Mariano Rubio, Nariman Almnini, Patrick De Luna, Sheila Toro, and Syed Hasan. We welcome all of you. We hope you can enjoy 3 enriching and fulfilling years. During this episode, you will hear a conversation between Dr. Arreaza and Dr. Song. Some elements of the case have been modified or omitted to protect the patient's confidentiality. 1. Introduction to the case: Headache. A 40-year-old male with no significant PMH presents to the ED in a local hospital due to over a month history of headaches. Per the patient, headaches usually start from the bilateral temporal side as a tingling sensation, and it goes to the frontal part of the head and then moves up to the top of the head. 8 out of 10 severities were the worst. Pt reports sometimes hypersensitivity to outdoor sunlight but not indoor light. OTC ibuprofen was helpful for the headache, but the headache always came back after a few hours. The patient states that if he gets up too quickly, he feels slightly dizzy sometimes, but it is only for a short period of time. There was only one episode of double vision lasting a few seconds about 2 weeks ago but otherwise, the patient denies any other neurological symptom. He does not know the cause of the headache and denies any similar history of headaches in the past. The patient denies any vomiting, chest pain, shortness of breath, cough, abdominal pain, or joint pain. The patient further denies any recent traveling or sick contact. He does not take any chronic medication. The patient denies any previous surgical history. He does not smoke, drink, or use illicit drugs. What are your differential diagnoses at this moment? Primary care: Tension headache, migraines, chronic sinusitis, and more.2. Continuation of the case: Fever and immigrant.Upon further inquiries, the patient endorses frequent “low-grade fever” but he did not check his temperature. He denies any significant fatigue, night sweats, or weight loss. He migrated from Bolivia to the U.S. 12 years ago and has been working as a farm worker in California for the past 10 years. He is married. His wife and daughter are at home in Bolivia. He is currently living with friends. He is not sexually active at this moment and denies having any sexual partners. Differential diagnoses at this moment?  Tension headache, migraine, infections, autoimmune disease, neurocysticercosis. 3. Continuation of the case: Antibiotics and eosinophilia. As we kept asking for more information, the patient remembered he visited a clinic about four months ago for a dry cough and was told he had bronchitis and was given antibiotics and the cough got better after that. He went to another local hospital ED one month after that because the cough came back, now with occasional phlegm and at that time he also noticed two “bumps” on his face but nothing significant. After a CXR at the ED, the patient was diagnosed with community-acquired pneumonia and sent home with cough medication and another course of antibiotics. His cough improved after the second round of antibiotics. We later found on the medical record that the CXR showed “mild coarse perihilar interstitial infiltrates of unknown acuity”. His blood works at the ED showed WBC 15.2, with lymphocyte 21.2%, monocyte 10.1%, neutrophil 61.7%, eosinophil 5.9% (normally 1-4%), normal kidney, liver functions, and electrolytes, and prescribed with benzonatate 100mg TID and doxycycline 100mg bid for 10 days. He went to the same ED one month before he saw us for headache and fever (we reviewed his EMR, and temp was 99.8F at the ED). After normal CBC, CMP and chest x-ray. The patient was diagnosed with a viral illness and discharged home with ibuprofen 400mg q8h.Due to the ongoing symptoms of headache and fever, the patient went back to the same clinic he went to four months ago for a dry cough and requested a complete physical and blood work. The patient was told he had a viral condition and was sent home with oseltamivir (Tamiflu®) for five days. However, the provider did order some blood work for him. Differential diagnoses at this moment?  Patients with subacute meningitis typically have an unrelenting headache, stiff neck, low-grade fever, and lethargy for days to several weeks before they present for evaluation. Cranial nerve abnormalities and night sweats may be present. Common causative organisms include M. tuberculosis, C. neoformans, H. capsulatum, C. immitis, and T. pallidum. At his physical exam visit, the patient actually asked the provider specifically to check him for coccidiomycosis because of his job as a farm worker and he heard from his friends that the infection rate is pretty high in the Central Valley of California. His serum cocci serology panel showed positive IGG and IGM with CF titer of 1:128. His HIV, syphilis, HCV, HBV are all negative. The patient was told by that clinic to come to ED due to his history of headache, fever, and very high serum coccidiomycosis titer.  The senior and resident intern were on the night shift that night and we were contacted by the ED provider at around 9:30 pm for this patient. When reviewing his ED record, his vitals were totally normal at the ED, the preliminary ED non-contrast head CT showed no acute intracranial abnormality. A lumbar puncture was performed by the ED provider, which showed WBCs (505 - 71%N, 20%L, 7%M), RBC (1), glucose (19), and protein (200). CSF: High Leukocytes, low glucose, and high protein.On the physical exam, the patient was pleasant and cooperative, he was A&O x 4, he had a normal examination except for two brown healing small nodules on his forehead and left cheek and slight neck stiffness. At that point, we knew the patient most likely had fungal meningitis by cocci except for the predominant WBC in his CSF fluid was neutrophil not the more typical picture of lymphocyte dominant. And because of his very benign presentation and subacute history, we were not 100% sure if we had a strong reason to admit this patient. We thought this patient could be managed as an outpatient with oral fluconazole and referred to infectious disease and neurology. 4. Continuation of case: Admission to the hospital.Looking back, one thing that was overlooked while checking this patient in the ED was the LP opening pressure. Later, the open pressure was reported as 340mm H2O (very high). The good thing was, after speaking to the ED attending and our attending, the patient was admitted to the hospital and started on oral fluconazole.  Three hours after the admission, a rapid response was called on him. While the floor nurses were doing their check-in physical examination, the patient had a 5-minute episode of seizure-like activity which included bilateral tonic arm/hand movements, eye deviation to the left, LOC unresponsive to sternal rub, and the patient desaturated to 77%. He eventually regained consciousness after the seizure and pulse oximetry increased to 100% on room air. The patient was started on Keppra and seen by a neurologist the following day. His 12-hour EEG was normal, but his head MRI showed “diffuse thickening and nodularity of the basal meninges are seen demonstrating enhancement, suggesting chronic meningitis, possibly related to cocci. Other etiologies including sarcoidosis and TB meningitis and/or infiltration by metastatic process/lymphoma are not excluded. The ventricles are slightly prominent in size”. MRI of the cervical, thoracic, and lumbar spines also showed extensive diffuse leptomeningeal thickening, extensive meningitis, and nodular dural thickening. Also, his chest x-ray showed “some heterogeneity and remodeling of the distal half of the left clavicle. Metabolic bone disease, infectious etiology and/old trauma considered”. This could also be due to disseminated cocci infection. The infectious disease doctor saw this patient and recommended continuing with fluconazole, serial LPs until opening pressure is less than 250 mmH2O and neurosurgery consultation for possible VP shunt placement. The neurologist recommended the patient continue with Keppra indefinitely in the context of structural brain damage secondary to cocci meningitis.Take home points: Suspect cocci meningitis in patients with subacute headache associated with respiratory symptoms, new skin lesions, photophobia, neck stiffness, nausea, vomiting, eosinophilia, erythema nodosum (painful nodules on the anterior aspect of legs). Other symptoms to look for include arthralgias, particularly of the ankles, knees, and wrists.____________________Brief summary of coccidiomycosis. Etiology Coccidioidomycosis, commonly known as Valley fever, is caused by dimorphic soil-dwelling fungi of the genus Coccidioides (C. immitis and C. posadasii). They are indistinguishable in clinical presentation and routine laboratory test results.1, 2, 3, 5Epidemiology In the United States, endemic areas include the southern portion of the San Joaquin Valley of California and the south-central region of Arizona. However, infection may be acquired in other areas of the southwestern United States, including the southern coastal counties in California, southern Nevada, southwestern Utah, southern New Mexico, and western Texas (including the Rio Grande Valley). There are also cases in eastern Washington state and in northeastern Utah. Outside the United States, coccidioidomycosis is endemic to northern Mexico as well as to localized regions of Central and South America.1, 2Overall, the incidence within the United States increased substantially over the 1998-2019, most of that increase occurred in south-central Arizona and in the southern San Joaquin Valley of California. From 1998 to2019, reported cases in California increased from 719 to 9004.1, 6The risk of infection is increased by direct exposure to soil harboring Coccidioides. Past outbreaks have occurred in military trainees, archaeologists, construction or agricultural workers, people exposed to earthquakes or dust storms. However, in endemic areas, many cases of Coccidioides infection occur without obvious soil or dust exposure and are not associated with outbreaks. Change in population, climate change, urbanization and construction activities, and increased awareness and reporting, are possible contributing factors.1, 2, 5 Pathology In the soil, Coccidioides organisms exist as filamentous molds. Small structures called arthroconidia from the hyphae may become airborne for extended periods. Arthroconidia are usually 3-5 μm—small enough to evade bronchial tree mucosal mechanical defenses and reach deep into the lungs.1, 3Once inhaled by a susceptible host into the lung, the arthroconidia develop into spherules (theparasitic existence in a host), which are unique to Coccidioides. Endospores from ruptured spherules can themselves develop into spherules, thus propagating infection locally.1, 3, 5Although rare cases of solid organ donor-derived or fomite transmitted infections have been reported, coccidioidomycosis does not occur in person-to-person or zoonotic contagion, and transplacental infection in humans has never been documented.2, 5Cellular immunity plays a crucial role in the host's control of coccidioidomycosis. Among individuals with decreased cellular immunity, Coccidioides may spread locally or hematogenously after an initial symptomatic or asymptomatic pulmonary infection to extrathoracic organs.1, 3, 7Clinical manifestationThe majority of infected individuals (about 60%) are completely asymptomatic. Symptomatic persons (40% of cases) have symptoms that are related principally to pulmonary infection, including cough, dyspnea, and pleuritic chest pain. Some patients may also experience fever, headache (common finding in early-stage infection and does not represent meningitis), fatigue, night sweats, rash, myalgia.1, 2, 3, 5In most patients, primary pulmonary coccidioidomycosis usually resolves in weeks without sequelae and lifelong immunity to reinfection. However, some patients may develop chronic pulmonary complications, such as nodules or pulmonary cavities, or chronic fibrocavitary pneumonia. Some individuals with intense environmental exposure or profoundly suppressed cellular immunity (e.g., in patients with AIDS) may develop a primary pneumonia with diffuse reticulonodular pulmonary process in association with dyspnea and fever.1, 3, 5Fewer than 1% of infected individuals develop extrathoracic disseminated coccidioidal infection. Common sites for dissemination include joints and bones, skin and soft tissues, and meninges. One site or multiple anatomic foci may be affected. 1, 2, 3, 7It is estimated that coccidioidal meningitis, the most lethal complication of coccidioidomycosis, affects only 0.1% of all exposed individuals. Patients with coccidioidal meningitis usually present with a persistent headache (rather than a self-limited headache in some patients with primary pulmonary infection), with nausea and vomiting, and sometimes vision change. Some may also develop altered mental status and confusion. Meningismus such as nuchal rigidity, if present, is not severe.Hydrocephalus and cerebral infarction may develop in some cases. Papilledema is more commonly observed in pediatric patients.1, 3, 4, 5, 7When meningitis develops, most patients may not have any respiratory symptoms nor radiographic manifestation of pulmonary infection. However, a large number of these individuals also present with other extrathoracic lesions.7DiagnosisAlthough early diagnosis carries obvious benefits for patients and the health care systems as a whole (e.g., decreases patient anxiety, reduces the cost of expensive and invasive tests, removes the temptation for empirical antibacterial or antiviral treatments, and allows for early detection of complications), considerable diagnostic delays up to several weeks to months are common in both endemic areas and non-endemic areas.3, 7 Most symptomatic persons with coccidioidal infection present with primarily pulmonary symptoms and are often misdiagnosed as community-acquired bacterial pneumonia and treated with antibiotics. In endemic areas like south-central Arizona, previous studies found up to 29% of community-acquired pneumonia is caused by coccidioidomycosis. Healthcare providers thus should maintain a high clinical suspicion for coccidioidomycosis when evaluating persons with pneumonia who live in or have traveled to endemic areas recently. Elevated peripheral-blood eosinophilia of over 5%, hilar or mediastinal adenopathy on chest radiography, marked fatigue, and failure to improve with antibiotic therapy should prompt suspicion and testing for infection with coccidioidomycosis in endemic areas.1, 3, 5Serological testing plays an important role in establishing a diagnosis of coccidioidomycosis. Enzyme immunoassay (EIA) to detect IgM and IgG antibodies is highly sensitive and therefore commonly used as the screening tool. Immunodiffusion is more specific but less sensitive than enzyme immunoassay. It is used to confirm the diagnosis of positive EIA test results. Complement fixing (CF) test, which indirectly detects the presence of coccidioidal antibodies by testing the consumption of serum complement, are expressed as titers. Serial measurements of titers are of not only diagnostic but also prognostic value.1, 2, 3, 5Other methods, including culture, microscopic, or polymerase chain reaction (PCR) exam on tissue or respiratory specimens, are limited by their availability, sample obtaining and handling, or lack of sufficient evaluation.1, 2, 3, 5Cerebrospinal fluid (CSF) examination in coccidioidal meningitis usually demonstrates lymphocyte dominated elevation of leukocytes, although polymorphonuclear leukocyte dominance can also be seen in the early stage of the infection. Profound hypoglycorrhachia and elevated protein levels in CSF examination are also very common in coccidioidal meningitis.1, 7Although isolating Coccidioides from CSF or other CNS specimens are diagnostic for coccidioidal meningitis, in practice, diagnoses are often made based on the combination of clinical presentation, CSF examination that suggesting fungal infection, and positive Coccidioides antibodies found in CSF.7Imaging, especially enhanced magnetic resonance imaging (MRI), can help in diagnosing coccidioidal meningitis. Basilar leptomeningeal enhancement is a more common finding even though hydrocephalus, cerebral infarction, and vertebral artery aneurysm can also be seen.7TreatmentMost patients with focal primary pulmonary coccidioidomycosis do not require antifungal therapy. According to 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline, antifungal therapy should be considered in patients with concurrent immunosuppression that adversely affect cellular immunity (e.g., organ transplant patients, AIDS in HIV-infected patients, and patients receiving anti–tumor necrosis factor therapy) and those with significantly debilitating illness, extensive pulmonary involvement, with concurrent diabetes, pregnant women, or who are otherwise frail because of age or comorbidities. Some experts would also include African or Filipino ancestry as indications for treatment. Conversely, humoral immunity comprise splenectomy, hypocomplementemia, or neutrophil dysfunction syndromes are not major risk factors for this disease.1, 2, 3, 4, 5Triazole antifungals (fluconazole or itraconazole) are currently considered as the first-line medications used to treat most cases of coccidioidomycosis. Amphotericin B is reserved for only the most severe cases of dissemination and patients with coccidioidal meningitis in whom triazole antifungal therapy has failed. It is also the choice of therapy for coccidioidomycosis in pregnant women during the first trimester because of the possible teratogenic effect of high-dose triazole therapy during this period of time.1, 3, 4, 5Treating coccidioidal meningitis (CM) poses a special challenge because untreated meningitis is nearly always fatal. Lifelong therapy is recommended for CM because the majority 80% patients with CM experience relapse when therapy is stopped despite initial response to antifungal treatment. Shunting of CSF is required in cases of meningitis complicated by hydrocephalus.1, 3, 4, 5, 7Prevention Avoidance of direct contact with contaminated soil in endemic areas (e.g., respirator use by construction workers) may reduce disease risk, although clear evidence of its benefit is lacking.1, 5Some special population groups may benefit from prophylactic use of antifungals, such as those about to undergo allogeneic solid-organ transplantation or patients with a history of active coccidioidomycosis or a positive coccidioidal serology in whom therapy with tumor necrosis factor α antagonists is being initiated. The administration of prophylactic antifungals is not recommended for HIV-1-infected patients even if they live in an endemic region.1, 5Conclusion: Now we conclude episode number 164, “More than just a headache.” Dr. Song explained that a headache with an indolent course, accompanied by subacute respiratory symptoms, nausea, vomiting, photophobia, neck stiffness, and skin lesions can be secondary to Valley Fever. The Central Valley of California, as well as other areas with dry climate, are endemic and we need to keep this disease in our differential diagnosis.This week we thank Hector Arreaza and Zheng (David) Song. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Roos KL, Tyler KL. Acute Meningitis. McGraw Hill Medical. Published 2023. Accessed August 18, 2023. https://accessmedicine.mhmedical.com/content.aspx?bookid=2129§ionid=192020493Information for Healthcare Professionals. Published 2023. Accessed August 18, 2023. https://www.cdc.gov/fungal/diseases/coccidioidomycosis/health-professionals.html#printValley Fever (Coccidioidomycosis) a Training Manual for Primary Care Professionals. Accessed August 18, 2023. https://vfce.arizona.edu/sites/default/files/valleyfever_training_manual_2019_mar_final-references_different_colors.pdfAmpel NM. Coccidioidomycosis. Idsociety.org. Published July 27, 2016. Accessed August 18, 2023. https://www.idsociety.org/practice-guideline/coccidioidomycosis/Herrick KR, Trondle ME, Febles TT. Coccidioidomycosis (Valley Fever) in Primary Care. American Family Physician. 2020;101(4):221-228. Accessed August 18, 2023. https://www.aafp.org/pubs/afp/issues/2020/0215/p221.htmlValley Fever Statistics. Published 2023. Accessed August 18, 2023. https://www.cdc.gov/fungal/diseases/coccidioidomycosis/statistics.htmlUpToDate. Uptodate.com. Published 2023. Accessed August 18, 2023. https://www.uptodate.com/contents/coccidioidal-meningitis?search=7%20Coccidioidal%20meningitis&source=search_result&selectedTitle=1~10&usage_type=default&display_rank=1Royalty-free music used for this episode: Tropicality by Gushito, downloaded on July 20, 2023, from  https://www.videvo.net/

In this episode, Robert Wong, MD, MS, and a patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including:Opportunities to improve patient education, including education for expectant mothers with HBVPotential cultural considerations that may result in delayed HBV diagnosis and care Stigma reduction with universal HBV screening and vaccinationStrategies to improve patient education (eg, online resources, advocacy groups, use of layman's terms and diagrams, repetition)Presenter: Robert Wong, MD, MS Clinical Associate Professor Division of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: https://bit.ly/49TuZ8UGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:Current therapiesStudies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDFKaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis BEarly vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV TransmissionInvestigational functional cure strategiesB-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV InfectionMARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV InfectionREEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHBHBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV InfectionCVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV InfectionPresenter:Nancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical Center Chicago, IllinoisLink to full program: https://bit.ly/47XJlU4

In this episode, Nancy Reau, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus and hepatitis delta virus, including:The importance of patient education along the care continuumEnsuring smooth transitions of care and communication between medical teamsScreening hepatitis delta in persons with chronic hepatitis BManaging hepatitis delta, including considerations for clinical trialsPromoting patient advocacyPresenter: Nancy Reau, MDProfessor of Medicine Chief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: bit.ly/3SrMuGOGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screeningPresenters:Douglas Dieterich, MDDirector, Institute for Liver MedicineProfessor of MedicineDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkCamilla S. Graham, MD, MPHCo-Director, Viral Hepatitis ClinicDivision of Infectious DiseasesBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsRobert Wong, MD, MS Clinical Associate ProfessorDivision of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaLink to full program:https://bit.ly/3TuqFHILink to the slides: https://bit.ly/4atS42z

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screeningPresenters:Douglas Dieterich, MDDirector, Institute for Liver MedicineProfessor of MedicineDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkCamilla S. Graham, MD, MPHCo-Director, Viral Hepatitis ClinicDivision of Infectious DiseasesBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsRobert Wong, MD, MS Clinical Associate ProfessorDivision of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaLink to full program:https://bit.ly/3TuqFHILink to the slides: https://bit.ly/4atS42z

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screeningPresenters:Douglas Dieterich, MDDirector, Institute for Liver MedicineProfessor of MedicineDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkCamilla S. Graham, MD, MPHCo-Director, Viral Hepatitis ClinicDivision of Infectious DiseasesBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsRobert Wong, MD, MS Clinical Associate ProfessorDivision of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaLink to full program:https://bit.ly/3TuqFHILink to the slides: https://bit.ly/4atS42z

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screeningPresenters:Douglas Dieterich, MDDirector, Institute for Liver MedicineProfessor of MedicineDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkCamilla S. Graham, MD, MPHCo-Director, Viral Hepatitis ClinicDivision of Infectious DiseasesBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsRobert Wong, MD, MS Clinical Associate ProfessorDivision of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaLink to full program:https://bit.ly/3TuqFHILink to the slides: https://bit.ly/4atS42z

In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:Current therapiesStudies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDFKaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis BEarly vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV TransmissionInvestigational functional cure strategiesB-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV InfectionMARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV InfectionREEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHBHBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV InfectionCVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV InfectionPresenter:Nancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical Center Chicago, IllinoisLink to full program: https://bit.ly/47XJlU4

Are we treating HBV early enough? Is it time to move the goalposts regarding the timing of treatment initiation? What are the potential benefits of earlier treatment?To answer these questions, Ira M. Jacobson, MD, leads a panel discussion with Tatyana Kushner, MD, MSCE, and Paul Y. Kwo, MD, exploring which patients with HBV we should be treating, including a focus on:Guideline-based treatment recommendations and their limitationsData describing the relationship between viral suppression and HBV DNA integrationMore expansive indications for HBV treatment based on virologic considerationsPresenters:Ira M. Jacobson, MDProfessor of MedicineDirector of HepatologyNYU Langone HealthNew York, New YorkTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of Medicine Director of Hepatology Stanford University School of MedicinePalo Alto, CaliforniaLink to the full program: https://bit.ly/3R1PMi4Link to the slides: https://bit.ly/3N5Fpsm

Should quantitative HBsAg testing be used routinely in clinical practice for patients living with chronic hepatitis B?In this episode, Tatyana Kushner, MD, MSCE, discusses the role of quantitative hepatitis B surface antigen testing in people living with chronic hepatitis B, including:Determination of inactive carrier statusPrediction of liver fibrosis/cirrhosisPrediction of hepatocellular carcinoma developmentMonitoring response to treatment, including future HBV treatments in the development pipelinePrediction of HBsAg lossJoining her for the panel discussion are Ira M. Jacobson, MD, and Paul Y. Kwo, MD.Presenters:Ira M. Jacobson, MDProfessor of MedicineDirector of HepatologyNYU Langone HealthNew York, New YorkTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of Medicine Director of Hepatology Stanford University School of MedicinePalo Alto, CaliforniaLink to the full program: https://bit.ly/3R1PMi4Link to the slides: https://bit.ly/3N5Fpsm

“I think that as oncology nurses, we need to keep ourselves really educated and up to date with these new therapies, because I honestly feel like we still haven't really seen the long-term effects of this treatment,” ONS member Lisa Parks, MS, APRN-CNP, ANP-BC, nurse practitioner in hepatobiliary surgery at The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center in Columbus, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about recognizing hepatic complications and understanding the basics of its symptom management strategies. This episode is part of a series on cancer symptom management basics; the others are linked below.   You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0  Earn 0.5 NCPD contact hours of nursing continuing professional development (NCPD), which may be applied to the disease-related biology, treatment, or symptom management, palliative care, supportive care ILNA categories, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by September 22, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.22, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: The learner will report an increase in knowledge in cancer symptom management basics and hepatic complications.   Episode Notes  Complete this evaluation for free NCPD.   Oncology Nursing Podcast:  Episode 269: Cancer Symptom Management Basics: Gastrointestinal Complications  Episode 256: Cancer Symptom Management Basics: Hematologic Complications  Episode 250: Cancer Symptom Management Basics: Dermatologic Complications   Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications  ONS Voice article: To Prevent Hepatotoxicity, Monitor Liver Function During Cancer Treatment  Clinical Journal of Oncology Nursing articles:   Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management  Identification and Management: Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Related to Hematopoietic Stem Cell Transplantation  Use of Hepatic Artery Infusion Pumps in the Treatment of Hepatic Metastases  ONS courses:  ONS/ONCC Chemotherapy Immunotherapy Certificate Course  ONS/ONCC Radiation Therapy Certificate Course  ONS books:  Cancer Basics (third edition)https://www.ons.org/books/cancer-basics-third-edition  Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition)  Manual for Radiation Oncology Nursing Practice and Education (fifth edition)  Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition)   American Gastroenterological Association  American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org    Highlights From Today's Episode  “There is something called chemotherapy-induced liver injury. What the chemotherapy does is it has a direct hepatotoxic effect on the hepatocytes themselves. If you have preexisting liver disease such as cirrhosis, it can lead to very severe hepatotoxicity because the function of the liver is already compromised by the damage previously done to it.” TS 3:47  “The American Gastroenterological Association published guidelines on the management of HBV reactivation for patients during immunosuppressive treatment, and they basically do recommend any patients with a hep B virus that they receive antiviral prophylaxis to prevent this reactivation from occurring. Also in 2008, the CDC recommended universal HBV screening for all patients before administering chemotherapy. This one you see most commonly in patients who receive chemotherapy for a hematological cancer following hemopoietic stem cell transplantation.” TS 14:19  “One of the most common things that I've encountered in my practice is that there seems to be a thought that once hepatic complications are identified, there is treatment for this, and in these patients, we can't reverse liver injury. Really, what we offer these patients is supportive care. These patients often can decompensate really quickly, and often these patients may require being transferred to the intensive care unit and it's not because there's any intervention that we're going to do. But I think it's very frustrating for nurses to see these severe liver injuries, that are life threatening, and not to be able to do anything about it.” TS 19:06 

What does it take to pioneer groundbreaking T-cell immunotherapies and vaccines for infectious diseases and cancer? Join us for this episode of BioTalk, where we sit down with Bill Enright, a seasoned biotech executive with a remarkable track record spanning over three decades. Bill brings a wealth of experience in building and financing both privately held and publicly traded companies, making his mark in various roles within the life science/biotech industry. Bill offers a compelling update in this installment since his previous appearance on BioTalk. Learn about the intriguing journey that led Vaccitech, a clinical-stage T cell immunotherapy and vaccine company, to select Montgomery County, MD, within the thriving BioHealth Capital Region, for its new site. Delve into the intricacies of their pioneering platform, which harnesses the power of immunotherapy to elicit robust T cell responses and antibodies against infectious agents and tumors. Get an insider's perspective as Bill provides clinical updates on their groundbreaking work, discussing major milestones in critical areas like HBV, HPV, PCA, and VTB, among others. Explore Vaccitech's path forward as Bill sheds light on their next significant milestones and strategic plans to expand their presence within the United States. Don't miss this exclusive conversation with Bill Enright as he shares insights into the dynamic world of immunotherapy and Vaccitech's mission to transform the disease treatment and prevention landscape.

In this episode, Joseph Ahn, MD, MS, MBA; Christina Delacruz Leyson, MD; and Alice Chan, a person who experienced pregnancy as a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in people of childbearing potential and their infants, including:HBV screening and vaccination in pregnancyManagement of pregnant people who are HBsAg positiveInfant careBreastfeedingPresenters: Joseph Ahn, MD, MS, MBAProfessor of Medicine, Section ChiefDivision of Gastroenterology and HepatologyOregon Health & Science UniversityPortland, OregonChristina Delacruz Leyson, MDAssociate ProfessorMedical Director, Liver Transplant ProgramProgram Director, Hepatology FellowshipUniversity of KentuckyLexington, KentuckyAlice Chan, person living with chronic hepatitis BLink to downloadable slides:https://bit.ly/3rXLTC7Link to program: https://bit.ly/3L3Kz6l

Dan Wilson returns to TWiV to debunk vaccine misinformation by RFK Jr. during his recent appearance on the Joe Rogan Experience. Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit, Kathy Spindler, and Brianne Barker Guest: Dan Wilson Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server Joe Rogan's worst misinformation yet, with RFK Jr. (YouTube) Every first vaccine has been tested in placebo-controlled trials before going to market. Polio Measles HPV COVID-19 HepB Haemophilus influenzae B Pertussis Diphtheria Tetanus Pneumococcal Mumps Meningococcal Chickenpox HepA KiGGS Study results on atopic diseases after vaccination (Vaccine) Vaccine history by year (CHOP) Financing vaccines in the 21st Century (Nat Acad Press) DALY rates from non-communicable diseases (Our World in Data) Science loses one to creationism (WaPo) Children's Health Defense (Wikipedia) COVID-19 vaccines saved 3 million US lives (CIDRAP) Beyond the Noise with Paul Offit (YouTube) Letters read on TWiV 1026 Timestamps by Jolene. Thanks! Weekly Picks Dickson – Jazz G.O.A.T.S – Louis Armstrong, Duke Ellington, Ella Fitzgerald Brianne – Defining the Anthropocene? Kathy – How to use your thermostat on A/C Rich – Star Trek: Strange New Worlds Vincent – Step Aside, Joe Biden Listener Picks Kim – Virus found in a boreal lake links ssDNA and dsDNA viruses and Structure of ssDNA bacteriophage ΦCjT23 provides insight into early virus evolution Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:Hepatitis B virusDurability of response with bepirovirsenHBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfaHepatitis delta virus96-week follow-up of immediate vs delayed bulevirtideOff-treatment response for lonafarnib + ritonavir ± pegIFN-alfa Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogueHepatitis C virusCollaborative service at opiate substitution treatment clinic to improve linkage to care in IrelandNurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United KingdomFIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of healthPresenter:Stefan Zeuzem, MDProfessor of Medicine Chief, Department of Medicine JW Goethe University Hospital Frankfurt, GermanyLink to full program: https://bit.ly/3JQQj3J

In this episode, Robert S. Brown, Jr., MD, MPH; Nancy Reau, MD; and Eric, a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in older adults, including:Awareness of HBV and CHB in older adultsUpdated HBV screening and vaccination recommendationsMonitoring of renal and bone diseaseAdjustment of monitoring and treatment as a person with HBV agesPresenters: Robert S. Brown, Jr., MD, MPHVincent Astor Distinguished Professor of MedicineChief, Division of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkNancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisEric, person living with chronic hepatitis BLink to downloadable slides: please link to VM404 downloadable slides when readyLink to program: bit.ly/3L3Kz6l

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for PWH coinfected with HBV and HCV. Listen as she covers:How HIV-ASSIST supports ART selection in primary careUpdates to viral hepatitis recommendations including:               CDC HBV screening and testing recommendations             AASLD simplified HCV treatment approach for PWHHIV-ASSIST for managing HIV/HBV coinfections, including ensuring that NRTIs that are effective for both HIV and HBV are included in an ART regimen and alerting the user when an additional HBV treatment is needed HIV-ASSIST for managing HIV/HCV coinfections, including showing how the HIV-ASSIST tool incorporates drug‒drug interaction considerations from the University of Liverpool HIV Drug Interaction CheckerCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Clinical OfficerNational Clinician Consultation CenterProfessorClinical Family Community MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaLink to full program: bit.ly/3pwaH2Y    

In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:Barriers to HDV screening, including limitations to AASLD guideline recommendationsUse of double reflex testing to improve HDV diagnosisConsiderations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDVUpdated CDC recommendations for HBV screening for all adults using a triple panel test Staging advanced liver disease in patients with HDVIndications for HDV treatment, including patients with low ALT levels and advanced or progressive liver diseaseTreatment landscape for HDVPersonal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosisUpdates on novel HDV therapies, including:Summary of efficacy data on bulevirtide from clinical trialsInterpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib Link to full program: bit.ly/3yp1Lxf

In this episode, Joseph Lim, MD; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and Jennifer Wild, MS, BSN, RN, OCN, discuss strategies for overcoming barriers to HBV care in Asian American people, including:HBV-related stigmaLanguage barriersHealth insurance navigationPresenters:Joseph Lim, MDProfessor of Medicine Director, Clinical HepatologyVice-Chief, Section of Digestive DiseasesYale University School of MedicineNew Haven, Connecticut Mindie H. Nguyen, MD, MAS, AGAF, FAASLDProfessor of Medicine (GI & Hepatology, Liver Transplant) Professor of Epidemiology & Population Health (By Courtesy)Director of Hepatology Fellowship Director of Hepatology ClerkshipStanford University Medical CenterPalo Alto, CaliforniaJennifer Wild, MS, BSN, RN, OCN Clinical NurseUCSF Helen Diller Family Comprehensive Cancer CenterGI Medical Oncology, Outpatient Hepatobiliary ProgramOakland, CaliforniaLink to downloadable slides: please link to VM401 downloadable slides when readyLink to program: please link to HEP 2023 HBV Key Communities VM (PRP5676) when ready

On February 27th, 1995 the bodies of Cheryl Feeney, and her two young children Tyler, age six, and Jennifer, one and a half would be found. They were brutally murdered in their home while Jon Feeney, Cheryl's husband was 90 miles away at a work conference. With a staged crime scene that made it look like a gang-related home invasion, Jon's lack of an alibi, and the extramarital affairs Jon had, he would be the only person to ever be named a suspect. This case took so many turns but is still unsolved.If you have any information on this triple homicide please contact Greene County Sheriff's office at (417) 868-4040Sources-https://apnews.com/article/5128910c872d3a814098cacb77281e0dhttps://fox4kc.com/news/missouri-news/murders-of-missouris-feeney-family-remain-unsolved-over-20-years-later/https://en.wikipedia.org/wiki/Vampire:_The_Masqueradehttps://www.reddit.com/r/coldcases/comments/zn90s2/a_family_massacre_did_a_father_and_science/https://www.news-leader.com/story/news/crime/2022/11/28/ozarks-true-crime-podcast-explores-feeney-family-murders-in-season-2/69656792007/https://www.childrenshospital.org/conditions/hepatitis-b#:~:text=HBV%20spreads%20through%20blood%2C%20saliva,hepatitis%20B%3A%20acute%20and%20chronic.https://www.newspapers.com/image/208170643/?terms=feeney&match=1https://www.newspapers.com/image/208167539/?terms=feeney&match=1Ozark True Crime Podcast has an in-depth multi-episode podcast on this case.